DRD2 and glioblastoma: Using shRNA technology to interfere with the expression of target genes, the research team performed genome-wide screening for genes associated with GBM growth and found integrated molecular signaling between epidermal growth factor receptor and dopamine receptor D2 (DRD2) in GBM (Li et al., 2014).